AI assistant
Sending…
Moderna, Inc. — Director's Dealing 2018
Dec 7, 2018
30610_dirs_2018-12-07_49b5cfc0-5bb2-487d-b951-dcb0b5a6fd65.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2018-12-07
Reporting Person: HUTT PETER BARTON (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 3924 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $0.04 | 2022-03-27 | Common Stock (802752) | Direct | |
| Stock Option (Right to Buy) | $10.90 | 2026-02-23 | Common Stock (23853) | Direct | |
| Stock Option (Right to Buy) | $19.15 | 2026-08-10 | Common Stock (9263) | Direct | |
| Stock Option (Right to Buy) | $12.21 | 2027-02-23 | Common Stock (42201) | Direct | |
| Stock Option (Right to Buy) | $14.22 | 2028-02-28 | Common Stock (40307) | Direct |
Footnotes
F1: This option is fully vested and exercisable.
F2: This option will become fully vested and exercisable on February 28, 2019.
More from Moderna, Inc.
Declaration of Voting Results & Voting Rights Announcements
2026
May 11
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Feb 25
Regulatory Filings
2026
Feb 23
Annual Report
2026
Feb 20
Director's Dealing
2026
Feb 13
Director's Dealing
2026
Feb 13